Access to Meds | Public Citizen

Don’t Buy Trump’s SOTU Claims on Drug Prices - Public Citizen In his State of the Union speech, President Trump is expected to tout progress from his administration on lowering drug prices for Americans, but the rhetoric will not match the reality. Here are the ...

The White House still has not published any of its deals with drugmakers, making its claims to have lowered prices very difficult to believe.

But we know for a fact Trump & GOP gave pharma an $8+ billion payout out of pockets of taxpayers & cancer patients via the Big Ugly Bill.

U.S. Global Health Spending Watch. The data are public. We just make them usable.

A new data tool for advocates: The Health Security Policy Academy has released its U.S. Global Health Spending Watch dashboard, which tracks how the U.S. government obligates and spends #GlobalHealth funds.

Explore the dashboard and accompanying blog:

More Than 100 Organizations Urge Countries to Resist Trump’s Trade Attacks, Protect Access to Affordable Medicines - Public Citizen WASHINGTON, D.C. — Public Citizen, Health GAP, and 99 expert organizations from around the world are calling for an approach…

Read the Principles for Access to Medicines and Trade: www.citizen.org/news/more-th...

Teal background, highlighted quote: "Pro-corporate, pro-monopoly models reinforced by the current trade order and exploited by the powerful are failing the world. Health must be a guarantee, not a bargaining chip." Blue background with caption: Over 100 organizations around the world detail principles for trade that ensure access to medicines."

The Trump administration is using U.S. trade power and extreme tariffs to bully other countries into binding agreements that undermine affordable and readily available access to medicines.

Experts from around the world offer an alternate vision:

New HHS petition Calls on the Trump Administration to Authorize Affordable Generic GLP-1 Drugs for Americans - Public Citizen WASHINGTON, D.C. — Today, Public Citizen filed a petition requesting that the United States Department of Health and Human Services…

Canada will get <$100 weight loss drugs, while Americans still struggle with the world’s highest prices.

We asked HHS to allow generic competition, overcoming the drugmakers’ patent barriers to improve access to expensive GLP-1s for weight loss, diabetes, and other conditions.

TrumpRx Lets Big Pharma Off the Hook - Public Citizen WASHINGTON, D.C. — This evening, President Trump is expected to announce the launch of TrumpRx – a direct-to-consumer website that…

Here's @publiccitizen.bsky.social's statement on TrumpRx:

www.citizen.org/news/trumprx...
#healthpolicy

📢 Ranafrica.org, @publiccitizen.bsky.social, People's Health Movement Kenya, and nearly 50 CSOs call on African leaders to demand equity and sovereignty rather than one-sided terms in new bilateral health agreements with the U.S.

Read the letter. ⬇️
www.ranafrica.org/news/african...

Civil Society Letter to EU HERA on Mpox/Smallpox Vaccine Procurement and Global Access - Public Citizen Dear Commissioner Lahbib and Director-General Fink-Hooijer, As organisations concerned with equitable access to health products in the European Union and…

📢Junto a @publiccitizen.bsky.social, @hai-org.bsky.social y otras 26 organizaciones pedimos a HERA (UE) más transparencia en el acuerdo con Bavarian Nordic para la compra de 8 millones de dosis de la vacuna mpox/smallpox

Aquí más info👉 www.citizen.org/article/civi...

Under threat of higher tariffs, the UK has agreed to give more money to Big Pharma, which will do NOTHING to lower the cost of medicines in the U.S.

More evidence that Trump’s tariffs are about helping his CEO buds, not working people.

Lenacapavir could sharply cut new HIV infections.

But only if people can actually get it.

Watch this brief video from @maybarduk.bsky.social on how monopoly power is limiting access, and why World AIDS Day is the moment to demand change.

www.instagram.com/p/DRh2CUIjl-Z/

Hundreds of Lobbyists Try to Clawback Medicare Drug Price Negotiations, Win Trump’s Favor - Public Citizen WASHINGTON, D.C. — Big Pharma and its allies have taken corporate influence in Washington to new heights, hiring more than…

Instead of giving handouts to Big Pharma at patients’ expense, Congress should work to lower drug costs, including by expanding price negotiations to allow all patients to access lower negotiated prices, even if they don’t have Medicare.

Read more here: www.citizen.org/news/hundred...

Does it pay? 

According to the CBO, one of the bills – the now-passed ORPHAN Cures Act – returns over $8 billion to pharma’s pockets. The proposed EPIC Act (that Trump essentially endorsed in an April EO) would return tens of billions more.

Big Pharma and its allies hired over 500 lobbyists this year to push 3 bills to erode a landmark reform that lets Medicare negotiate lower drug prices, according to our new report.

Their lobbyist hires outnumbered public interest advocates fighting the bad bills by 20-to-1.

Trade agreements must not stand in the way of health and access to medicines.

USMCA must be revised to remove extreme intellectual property provisions that keep medicine prices high, discourage competition, and ultimately impede access to medicine.

Thanks to health leaders Emily Bass, Mitchell Warren, Asia Russell, Amanda Banda, and Isata Dumbuya. And to our event co-hosts UNAIDS, Health GAP, People's Medicines Alliance, UAEM, Treatment Action Group, RESULTS, and Partners In Health.

We had a critical discussion about continuing the fight to bring medicines to all, with the first step being bringing that breakthrough — at that price — to the world.

Thanks to UNAIDS' Winnie Byanyima and Unitaid's Tenu Avafia for joining us today and for your leadership.

This week, the world learned that a new HIV prevention drug will be available for $40/year in 120 countries by 2027.

Yet millions of people in countries with growing HIV crises still are left out.

Today, health groups came together to support access for everyone, everywhere.